best practice for entrepreneurial ecosystems
Post on 14-Apr-2017
49 Views
Preview:
TRANSCRIPT
Dr. Christopher Hentschel
Ulysses Advisory Group
Best Practices: Entrepreneurial Ecosystems around the World
Ulysses Advisory Group
Basic Research Translational Research Product Development
Public-Private Ecosystems Optimize Healthcare R&D
Image here. Always this height, but width can vary
Neither the public nor theprivate sectors alone canDeliver optimal healthcareR&D.
But together there is thepotential for enormoussynergy and progress.
Examples 1: MRC , London UK;Example 2: MMV, Geneva (backup)
Public Goods Common Goods Private Goods
Ulysses Advisory Group
Public-Private Partnerships Optimize R&D productivity, particularly where incentives are needed
for the private sector to engage
Universities >>>> PPPs >>>>>> Industry PPPs help mitigate the ‘Valley of Death’ Phenomenon
• Rickets caused by lack of vitamin D (1916) • Discovery and development of penicillin (1940s)• Pioneered randomised controlled trial design (1940s)• Structure of DNA (1950s)• Discovery of link between smoking and cancer (1950s)• Clinical trials for radiotherapy for cancer (1960s)• Chemotherapy for leukaemia and monoclonal antibodies (1970s)• Invention of DNA fingerprinting (1980s)• Gene for Huntington’s disease discovered (1990s)• Humanised therapeutic antibodies in widespread use (2000s)• 22 Nobel prizes have been awarded to MRC-supported scientists• MRC Collaborative Centre (1987) > MRCT + MVM (2000 – Present)
MRC discoveries and developments Ulysses Advisory Group
Ulysses Advisory Group
NIMR 1913 – 2013 Francis Crick Institute (2016)
Ulysses Advisory Group
Translation of basic research takes time 1973: Mouse monoclonal antibodies isolated by César Milstein 1986: Michael Neuberger and Greg Winter ‘humanise’ mouse
antibodies and develops and the technology for producing antibodies in vitro
2003: MRC-developed Humira® licensed to treat arthritis 2008: 21 monoclonal antibody drugs on market for treating
breast cancer, leukaemia, asthma, arthritis, psoriasis and transplant rejection
2011: Antibodies make up 1/3 of new drugs for cancer, arthritis and asthma; global antibody market estimated to be worth $50bn
2016: Bio-similars market developing in emerging economies
Ulysses Advisory Group
MRC exploitation results since 1987• 92 new products and interventions launched, including several
‘blockbusters’.• Creation of 104 companies, 56 formed since 2006.• 578 patents granted since 2006, with around 30% licensed with
royalty income >$250m since 2006• More than 100 new industry collaborations are reported every
year• Lead partner in the new European Innovative Medicines Initiative
Ulysses Advisory Group
The European Union and the
pharmaceutical industry
have joined forces to make
drug R&D processes in Europe more
innovative and efficient,
enhance Europe’s competitiveness
& address key societal challenges
by forming
the biggest PPP in Life Science
8
EU Innovative Medicines Initiative:
Ulysses Advisory Group
Total IMI SME participants by countryUnited KingdomGermanyFranceBelgiumNetherlandsIcelandSpainDenmarkFinlandHungarySwedenItalyAustriaIrelandIsraelGreecePortugalSwitzerland
Ulysses Advisory Group Thank You For Your Attention
Confidential 10
For more information see ulyssesadvisorygroup.com
Ulysses Advisory Group
Backup Slides: MMV Geneva
Confidential 12
For more information see ulyssesadvisorygroup.com
Ulysses Advisory Group
MMV’s mission
“Medicines for Malaria Venture is a not-for-profit foundation dedicated to reducing the burden of malaria
in disease endemic countries by discovering, developing and delivering
new affordable antimalarials through effective public-private partnerships.”
MMV’s global network of R&D
GSK
=Pharmaceutical partners
=Universities/Institutes
=National Research Institutes
=National Agency
=International Agency
Swiss Tropical Institute
National Science & Technology Development Agency
GSK
University of California, San Francisco
Texas A&M
Jacobus
Albert Einstein College of Medicine
Howard Hughes Medical Institute
University of Mississippi
Gadjah MadaUniversity
University of Maryland
University of Washington Yale UniversityBMS
ImmtechInt’l
University of North CarolinaGeorgia State University
Tulane University
Paratek
University of Nebraska
Monash University
Novartis
Roche
University of Liverpool
Ranbaxy
WRAIR
AFRIMS
Guangzhou University of Traditional Chinese Medicine
Holleykin
Mahidol UniversityUniversity of Oxford/WellcomeTrust (Thailand, Vietnam, Kenya)
Shin Poong
WHO/TDR
Bayer
University of Iowa
Hong Kong University of Science & Technology
DFID
+ =Clinical trial sites (under review)
++
+++
GSK
=Pharmaceutical partners
=Universities/Institutes
=National Research Institutes
=National Agency
=International Agency
Swiss Tropical Institute
National Science & Technology Development Agency
GSK
University of California, San Francisco
Texas A&M
Jacobus
Albert Einstein College of Medicine
Howard Hughes Medical Institute
University of Mississippi
Gadjah MadaUniversity
University of Maryland
University of Washington Yale UniversityBMS
ImmtechInt’l
University of North CarolinaGeorgia State University
Tulane University
Paratek
University of Nebraska
Monash University
Novartis
Roche
University of Liverpool
Ranbaxy
WRAIR
AFRIMS
Guangzhou University of Traditional Chinese Medicine
Holleykin
Mahidol UniversityUniversity of Oxford/WellcomeTrust (Thailand, Vietnam, Kenya)
Shin Poong
WHO/TDR
Bayer
University of Iowa
Hong Kong University of Science & Technology
DFID
+ =Clinical trial sites (under review)
++
+++
Ulysses Advisory Group
Example: MMV’s Synthetic Peroxide Project - an example of International Partnership
Project team: University of Nebraska
Swiss Tropical Institute
Monash University
Roche/Basilea
Ranbaxy Laboratories
+ Outsourced Support• Cideim • St George’s Hospital Medical
School • Quintiles • Pharmalytics • Inveresk • Unimark • RCC • Fulcrum • Basilea • Cerb • Cerep • Maccine• MDS• ICGEB
Ulysses Advisory Group
JointR&D
MMV Input•$$$ •Drug Profile•Background IPR•Link to WHO/Policy•Malaria Expertise
Pharma•Chemistry IPR•Toxicology•Know How•Assets in Kind•Technology
MMV Gets•Rights in DEC•IPR in ‘Field’•Drug Supply•Return on non DEC Sales
Pharma/Bio Gets•Rights in non DEC•IPR outside ‘Field’•PR Benefit•HR Benefit•Validation of Technology
Public
Private
Inputs and Outputs of Joint R&D
top related